Precision Navigation to Improve Community Cancer Screening Participation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will evaluate whether a precision navigation intervention can help community residents at high risk for cancer complete recommended cancer screening. The study will be conducted in communities participating in an urban cancer screening program in China. Eligible participants will be adults aged 45 to 74 years who are permanent residents of participating communities and have been identified as being at high risk for at least one of five cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. Participants must not have completed the corresponding free clinical screening before enrollment. This is a dual-cohort, cluster randomized controlled trial. Communities, rather than individual participants, will be assigned to one of three groups: a precision navigation group, a usual health education group, or a waiting control group. Participants will be classified into two cohorts according to the number of cancers for which they are assessed as high risk. Cohort A will include participants at high risk for three or more cancers, and Cohort B will include participants at high risk for one or two cancers. Participants in the precision navigation group will receive a personalized navigation report matched to their risk profile. The report will explain the screening tests most relevant to them, help them understand screening choices, and provide practical steps to support screening completion. Participants in the usual health education group will receive general cancer screening education materials. Participants in the waiting control group will not receive active screening promotion during the main intervention period, but will receive general education materials after the primary assessment. The main outcome is whether participants complete the recommended cancer screening during follow-up. The study will also assess changes in screening-related decision conflict, anxiety, self-efficacy, and behavioral intention. The results may help improve community-based cancer screening programs and provide evidence for using personalized navigation strategies to increase screening participation among high-risk populations.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 45-74 lata
- •Stałe zamieszkanie w uczestniczącej społeczności przez co najmniej 6 miesięcy w ciągu ostatniego roku
- •Uczestnictwo w miejskim programie badań przesiewowych raka
- •Zidentyfikowanie przez program jako osoba zagrożona co najmniej jednym z pięciu typów raka
- •Niezakończone jeszcze badanie przesiewowe dla raka wysokiego ryzyka
- •Zdolność do wypełniania ankiet elektronicznych, ewentualnie z pomocą
✗ Disqualifies
- •Wcześniejsza diagnoza któregokolwiek z badanych typów raka
- •Poważne zaburzenia umysłowe lub stan psychiczny uniemożliwiający udział
- •Plan nieobecności w społeczności dłużej niż 3 miesiące w ciągu następnych 6 miesięcy
- •Aktualny udział w innym badaniu klinicznym mogącym wpłynąć na zachowanie dotyczące badań
Simplified criteria — AI translation
Trial details
- Minimum age
- 45 Years
- Maximum age
- 74 Years
- Last updated (source)
- September 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Huaihua Central Hospital (Huaihua Cancer Hospital)
Huaihua, China
Shaoyang Hospital of Traditional Chinese Medicine
Shaoyang, China
Yongzhou Central Hospital
Yongzhou, China
Trial contact
Haifan Xiao
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.